The outcome of metastatic gastric cancer is poor. Recent studies have shown that systemic inflammatory response markers such as NLR and PLR affect survival of GC pts. This study was carried out to create a prognostic model using inflammatory-based scores to predict survival in patients with metastatic GC before chemotherapy.
We studied the prognostic value of systemic inflammatory factors such as circulating white blood cell count and its components in 110 pts with metastatic GC receiving first-line chemotherapy. NLR and PLR were determined before starting chemotherapy. Median value was used to determine the cut-off levels for these biomarkers. Univariate and multivariate analyses were performed to examine the impact of inflammatory markers on overall survival (OS). Statistical analysis was performed by SPSS 21.0 software.
The median values of NLR and PLR were 2.22 (95% CI: 0.36-18.46) and 157.01 (95% CI: 32.79-720), respectively. Pts were divided into two groups according to the cut-off values (NLR:
This study suggests that elevated pretreatment NLR and PLR are independent predictors of short survival in metastatic GC patients treated with first-line chemotherapy.
Clinical trial identification
Legal entity responsible for the study
Second University of Naples
All authors have declared no conflicts of interest.